Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
IPO Year: 2018
Exchange: NASDAQ
Website: adialpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $8.00 | Buy | Rodman & Renshaw |
| 10/13/2021 | $12.00 | Buy | Brookline Capital |
| 6/29/2021 | $5.00 | Buy | Litchfield Hills |
Meeting to Take Place on July 25, 2025 Meeting's Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial's request for an End of Phase 2 meeting to discuss Adial's proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series B Warrants (the "Series B Warrants") to purchase up to 1,418,440 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), and Series C Warrants (the "Series C Warrants", and together with the Series B Warrants the "Existi
GLEN ALLEN, Va., May 01, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,274,692 was issued on April 15, 2025 by the United States Patent and Trademark Office (USPTO) covering a novel method of treating alcohol-related diseases and opioid-related disorders using AD04 in genetically identified patients. This newly issued patent strengthens Adial's intellectual property portfolio by covering the administration of AD04, the Company's investigational drug, as a precision
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024. Key Highlights Successful completion of AD04-103 pharmacokinetics (PK) study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron. Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership
FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval Adial moves forward with manufacturing of clinical supplies for upcoming Phase 3 clinical program in 2025 GLEN ALLEN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced a positive response from the U.S. Food and Drug Administration (FDA) regarding its proposed in vitro bridging strateg
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders Patent expands the identification of potential treatment candidates for AD04 administration based on the patient's unique genetic profile GLEN ALLEN, Va., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,226,401 was issued on February 18, 2025 by the United States Patent and Trademark Office (USPTO) expanding coverage of Adial's
GLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark Office. This patent expands the covered methods of identifying patients with specific genetic markers linked to substance use disorders and treating them with AD04, the Company's investigational new drug product. The treatment approach involves detecting the TT genotype of rs1042173 in the serotonin transporter gen
Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions Adial's formulation exhibited predictable bioavailability relative to the reference standard; near-micro doses exhibited dose proportionality in pharmacokinetic exposure, and no food effect Safety and tolerability consistent with ondansetron's extensive human use experience GLEN ALLEN, Va., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and rela
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, expanding the Company's intellectual property coverage. The patent covers a broader range of genotype combinations identified by the Company's proprietary genetic diagnostic for targeted treatment of alcohol use disorder (AUD) with AD04, the Company's lead investigational new drug product. These genotype combi
Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effect Marks final study needed for the upcoming FDA meeting for the Phase 3 study design and ongoing partnership discussions Continued excellent safety and tolerability findings, consistent with extensive human use experience with ondansetron GLEN ALLEN, Va., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced that it has completed a pharmacokinetics (PK)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
424B5 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
424B5 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
10-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
SC 13D/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024. Key Highlights Successful completion of AD04-103 pharmacokinetics (PK) study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron. Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership
GLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We reached an important milestone this quarter with the successful database lock of the pharmacokinetics study for AD04, our lead investigational, genetically targeted therapeutic for the treatment of Alcohol Use Disorder (AUD). The pharmacokinetics study is e
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "Throughout 2023 we
Charlottesville, Va., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Tony Goodman as Chief Operating Officer. A highly accomplished pharmaceutical industry executive and member of Adial's Board of Directors since 2017, Mr. Goodman will oversee the Company's strategic growth initiatives, including clinical development and commercial planning for AD04, as well as business development initiatives focused on partnership opportunities in the area
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00
Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00
Litchfield Hills initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $5.00
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)
Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities Adial in discussions with potential pharma partners Conference call to be held at 8:15 a.m. EST tomorrow CHARLOTTESVILLE, Va., March 06, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company") a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided an update on its regulatory strategy for AD04, the Company's lead compound for the treatment of Alcohol Use Disorder (A
CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will host a conference call and webcast on Tuesday, March 7, 2023, at 8:15 a.m. Eastern Time, to provide an update on its regulatory and partnering strategy for the United States and Europe. The company will also present and discuss the findings from its subgroup analysis of ONWARD data. A live audio webcast of the conference call and accompanying slide presentation may be accessed at https
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call to be held today at 1:00 p.m. Eastern Time CHARLOTTESVILLE, Va., July 20, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-sta
CHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it plans to report topline results from the Company's ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022. The Company plans to host a conference call at 1 PM Eastern Time on Wednesday (dial-in instructions to follow). About the ONWARD™ Trial The ONWARD Phase 3 clinical trial is a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, clinical study to evalu
CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 856729. A webcast of the call may be accessed at h
CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call may be accessed using the information provided on the Company's website at https://ir.adialpharma.com/ir-calendar. About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company
On track for trial completion in the first quarter of 2022 Adial to host business update call at 11AM Eastern today CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announces it has reached its full enrollment target of 290 subjects in the Company's ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin transporter and receptor genes. ONWARD tr
CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, will host a conference call at 11:00 A.M. Eastern Time today, August 20, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be available via telephone by dialing toll free 844-369-8770 for U.S. callers or +1 862-298-0840 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2463/42538 or on the Company's webs
CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW))) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Friday, August 20, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be available via telephone by dialing toll free 844-369-8770 for U.S. callers or +1 862-298-0840 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2463/42538 o